Adedapo O Bashorun, Larry Kotei, Ousubie Jawla, Abdoulie F Jallow, Aisha J Saidy, Ma-Ansu Kinteh, Arafang Kujabi, Tijan Jobarteh, Francis John Kanu, Simon A Donkor, Esu Ezeani, Sidat Fofana, Mbye Njie, Lamin Ceesay, Basit Jafri, Amanda Williams, David Jeffries, Brezesky Kotanmi, Bernardo A Mainou, Michael Ooko, Ed Clarke
BACKGROUND: Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating vaccine-derived poliovirus type 2 outbreaks following its WHO emergency use listing. This study reports data on the safety and immunogenicity of nOPV2 over two rounds of a campaign in The Gambia. METHODS: This observational cohort study collected baseline symptoms (vomiting, diarrhoea, irritability, reduced feeding, and reduced activity) and axillary temperature from children aged 6 weeks to 59 months in The Gambia before a series of two rounds of a nOPV2 campaign that took place on Nov 20-26, 2021, and March 19-22, 2022...
January 15, 2024: Lancet Infectious Diseases